VAIN 2-3 tedavisinde 5-florourasil kullanımı, tek merkez deneyimi
Makaleler > Tam Makale · 2023
Yazarlar: İlhan, Yunus, Sırma, Tuğçe, Yıldırım, Nuri, Akman, Levent, Terek, Cosan, Çelen, Firuze Beste, Hacıoğlu, Zeycan, Serin, Gürdeniz, Türeyici, Lena, Özsaran, Aydın
The Turkish Journal of Gynecologic Oncology, Uluslararası, 2023
Özet
Aim: Vaginal intraepithelial neoplasia (VAIN) has an average incidence of 0.2-0.3 per 100,000 women, which is much rarer than cervical intraepithelial neoplasia (CIN). It is mostly observed in the postmenopausal group.Material and Method: The study included 46 patients who were histopathologically diagnosed as VAIN 2-3 and initiated topical 5-fluorouracil treatment with the decision of the multidisciplinary council between October 2014 and December 2022, following the approval of the local ethics committee. Five patients with invasive vaginal cancer or cervical cancer involving the vagina were excluded.Results: The mean follow-up period was 32 months. Regression developed in 21 patients (51.2%), persistence in 15 (36.5%) and recurrence in 5 (12%). There were no patients with pregression.Conclusion: This study demonstrated the 51.2% success rate of intravaginal 5-fluorouracil treatment of women with high-grade vaginal intraepithelial neoplasia. It is recommended for the treatment of VAIN 2-3 due to its minimal side effects, low cost, and reasonable cure rate.